Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 2:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 457 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Seizures, Epileptic Clear all
Completed Phase 3 Interventional Results available

Lamotrigine Extended-Release In Elderly Patients With Epilepsy

NCT00516139
View directory record Official record
Conditions
Epilepsy
Interventions
Lamotrigine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
63
States / cities
Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 21, 2026, 2:48 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

NCT01529034
View directory record Official record
Conditions
Epilepsy
Interventions
USL261
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
12 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Sep 21, 2026, 2:48 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Relationship of HHV-6B Virus to Seizures and Brain Injury

NCT00597285
View directory record Official record
Conditions
Epilepsy, HHV6B Infection
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 21, 2026, 2:48 PM EDT
Enrolling by invitation Phase 3 Interventional

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

NCT06908226
View directory record Official record
Conditions
Developmental and Epileptic Encephalopathy
Interventions
LP352
Drug
Lead sponsor
Longboard Pharmaceuticals
Industry
Eligibility
2 Years to 66 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 21, 2026, 2:48 PM EDT
Enrolling by invitation Not applicable Interventional

Low-Intensity Focused Ultrasound Neuromodulation for Epilepsy

NCT07353918
View directory record Official record
Conditions
Epilepsy (Treatment Refractory), Epilepsy Comorbidities
Interventions
Low-intensity Focused Ultrasound, Sham
Device
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

Open-label Extension to Protocol 1042-0600

NCT00512317
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
ganaxolone
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

NCT04836559
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
JNJ-40411813, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 69 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Orlando, Florida • Port Orange, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Phase 4 Interventional

Treatment Trial for Psychogenic Nonepileptic Seizures

NCT00835627
View directory record Official record
Conditions
Convulsion, Non-Epileptic, Conversion Disorder, Depression, Stress Disorders, Post-Traumatic, Dissociative Disorders
Interventions
sertraline, CBT-ip, Combined (sertraline + CBT-ip), Standard Care
Drug · Behavioral · Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 95 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Stanford, California • Cincinnati, Ohio • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 9, 2014 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Phase 2 Interventional

Phase II BGG492 Capsule Extension for Partial Epilepsy

NCT01338805
View directory record Official record
Conditions
Partial Onset Seizures
Interventions
BGG492
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 66 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Tallahassee, Florida • Hamilton, New Jersey • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Closed-loop System Using Transcranial Direct Current Stimulation (tDCS) for Epilepsy

NCT01415362
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 21, 2026, 2:48 PM EDT
Terminated Phase 3 Interventional Results available

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

NCT00699283
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
43
States / cities
Little Rock, Arkansas • Garden Grove, California • Loma Linda, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 21, 2026, 2:48 PM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

NCT05067634
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Xcopri
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Palo Alto, California • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures

NCT00448916
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Month to 16 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
16
States / cities
Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 21, 2026, 2:48 PM EDT
Completed No phase listed Observational

Electrical Brain Stimulation to Reduce Epileptic Seizures

NCT00344877
View directory record Official record
Conditions
Temporal Lobe Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Phase 2 Interventional

Pediatric Epilepsy Trial in Subjects 1-24 Months

NCT00043875
View directory record Official record
Conditions
Epilepsy
Interventions
lamotrigine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
1 Month to 24 Months
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
34
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 21, 2026, 2:48 PM EDT
Terminated Phase 2 Interventional Results available

Buspirone Therapy for Localized Epilepsy

NCT01496612
View directory record Official record
Conditions
Anxiety Disorder, Seizures, Epilepsy, Partial Epilepsy, Depression
Interventions
Buspirone, Placebo
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Sep 21, 2026, 2:48 PM EDT
Terminated Not applicable Interventional

RNS System RESPONSE Study

NCT04839601
View directory record Official record
Conditions
Epilepsy, Partial Seizure, Neurostimulator; Complications, Drug Resistant Epilepsy, Focal Epilepsy
Interventions
RNS System
Device
Lead sponsor
NeuroPace
Industry
Eligibility
12 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Grand Rapids, Michigan • Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 21, 2026, 2:48 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures

NCT00524030
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
pregabalin 600 mg/day, pregabalin 150 mg/day
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
63
States / cities
Northport, Alabama • Phoenix, Arizona • Sun City, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

NCT04244175
View directory record Official record
Conditions
Seizures
Interventions
Placebo, CVL-865
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
37
States / cities
Little Rock, Arkansas • Downey, California • Loma Linda, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 21, 2026, 2:48 PM EDT
Completed No phase listed Observational

Non-Invasive Seizure Localization in Patients With Medically Refractory Localization Related Epilepsy: Synchronized MEG-EEG Recordings

NCT00071305
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 21, 2026, 2:48 PM EDT
Withdrawn Phase 2 Interventional

ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures

NCT05481905
View directory record Official record
Conditions
Focal Epilepsy
Interventions
ENX-101
Drug
Lead sponsor
Engrail Therapeutics INC
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • Downey, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

External Trigeminal Nerve Stimulation for Epilepsy

NCT01159431
View directory record Official record
Conditions
Epilepsy, Seizure Disorders
Interventions
Trigeminal Nerve Stimulation
Device
Lead sponsor
Olive View-UCLA Education & Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Los Angeles, California • Sylmar, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo

NCT00179517
View directory record Official record
Conditions
Seizure Disorder, Hypogonadism, Erectile Dysfunction
Interventions
Anastrozole 1mg, Placebo Oral Tablet
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Sep 21, 2026, 2:48 PM EDT
Completed Phase 3 Interventional Results available

Progesterone vs Placebo Therapy for Women With Epilepsy

NCT00029536
View directory record Official record
Conditions
Epilepsy
Interventions
Progesterone Lozenges, Matched Placebo Lozenges
Biological · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
13 Years to 45 Years · Female only
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
14
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 21, 2026, 2:48 PM EDT